We are live on ! Find out more
CRL icon

Charles River Laboratories

676 hedge funds and large institutions have $19.3B invested in Charles River Laboratories in 2021 Q3 according to their latest regulatory filings, with 83 funds opening new positions, 238 increasing their positions, 256 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more first-time investments, than exits

New positions opened: 83 | Existing positions closed: 37

33% more call options, than puts

Call options by funds: $128M | Put options by funds: $96.7M

25% more funds holding in top 10

Funds holding in top 10: 1620 (+4)

10% more capital invested

Capital invested by funds: $17.6B → $19.3B (+$1.74B)

6% more funds holding

Funds holding: 638676 (+38)

7% less repeat investments, than reductions

Existing positions increased: 238 | Existing positions reduced: 256

1.75% less ownership

Funds ownership: 94.66%92.91% (-1.7%)

Holders
676
Holders Change
+38
Holders Change %
+5.96%
% of All Funds
11.83%
Holding in Top 10
20
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+25%
% of All Funds
0.35%
New
83
Increased
238
Reduced
256
Closed
37
Calls
$128M
Puts
$96.7M
Net Calls
+$31.6M
Net Calls Change
+$32.8M
Name Holding Trade Value Shares
Change
Change in
Stake
CC
551
Cypress Capital
Tennessee
$229K +$230K +555 New
VVP
552
Venture Visionary Partners
Ohio
$224K +$226K +544 New
CC
553
Chicago Capital
Illinois
$223K +$224K +540 New
WJWM
554
Williams Jones Wealth Management
New York
$223K +$224K +540 New
SFI
555
Siemens Fonds Invest
Germany
$221K +$223K +536 New
MYAM
556
Meiji Yasuda Asset Management
Japan
$219K +$220K +530 New
AWM
557
Avior Wealth Management
Nebraska
$217K -$10.4K -25 -5%
MAP
558
Moody Aldrich Partners
Massachusetts
$217K +$218K +526 New
CCA
559
Checchi Capital Advisers
California
$208K -$208K -500 -50%
QCG
560
Quadrant Capital Group
Ohio
$207K +$10.8K +26 +5%
HCM
561
Hilton Capital Management
New York
$206K -$34.9K -84 -14%
WT
562
Washington Trust
Rhode Island
$206K
WPP
563
Whalerock Point Partners
Rhode Island
$206K +$208K +500 New
MAM
564
Marquette Asset Management
Minnesota
$205K
SI
565
Stephens Inc
Arkansas
$205K +$206K +496 New
FEM
566
Fulcrum Equity Management
Texas
$203K +$204K +492 New
FDCDDQ
567
Federation des caisses Desjardins du Quebec
Quebec, Canada
$194K -$162K -390 -45%
SIM
568
Sentry Investment Management
Wisconsin
$178K -$14.1K -34 -7%
CMBA
569
C.M. Bidwell & Associates
Hawaii
$178K
CFD
570
Creative Financial Designs
Indiana
$175K
DZ Bank
571
DZ Bank
Germany
$173K
PFBT
572
Parkside Financial Bank & Trust
Missouri
$171K +$4.57K +11 +3%
Capstone Investment Advisors
573
Capstone Investment Advisors
New York
$170K +$172K +413 New
Koshinski Asset Management
574
Koshinski Asset Management
Illinois
$160K +$161K +388 New
Canada Pension Plan Investment Board
575
Canada Pension Plan Investment Board
Ontario, Canada
$160K -$148K -357 -48%

CRL Hedge Fund Activity: Q3 2021 in Review

676 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2021, worth a combined $19.3B — up 9.9% from $17.6B a quarter earlier.

Buyers outnumbered sellers: 83 funds opened new CRL positions and 37 closed out — a net gain of 46 holders — while 238 added to existing stakes and 256 trimmed.

The largest buyer was Melvin Capital Management, opening a new position worth an estimated $156M. The largest seller was Ameriprise, cutting an estimated $242M.

  • 676 institutional investors held Charles River Laboratories (CRL) as of Q3 2021, up from 638 in Q2 2021.
  • Funds reported $19.3B of Charles River Laboratories stock for Q3 2021, up 9.9% quarter-over-quarter.
  • 83 funds opened new Charles River Laboratories positions in Q3 2021 and 37 closed out, a net change of +46 holders.
  • The largest Charles River Laboratories buyer in Q3 2021 was Melvin Capital Management, an estimated $156M added.
  • The largest Charles River Laboratories seller in Q3 2021 was Ameriprise, an estimated $242M sold.

Based on aggregated 13F filings for Q3 2021.